A thermal treatment system including a heat applying element for generating thermal doses for ablating a target mass in a patient, a controller for controlling thermal dose properties of the heat applying element, an imager for providing preliminary images of the target mass and thermal images during the treatment, and a planner for automatically constructing a treatment plan, comprising a series of treatment sites that are each represented by a set of thermal dose properties. The planner automatically constructs the treatment plan based on input information including one or more of a volume of the target mass, a distance from a skin surface of the patient to the target mass, a set of default thermal dose prediction properties, a set of user specified thermal dose prediction properties, physical properties of the heat applying elements, and images provided by the imager. The default thermal dose prediction properties are preferably based on a type of clinical application and include at least one of thermal dose threshold, thermal dose prediction algorithm, maximum allowed energy for each thermal dose, thermal dose duration for each treatment site, cooling time between thermal doses, and electrical properties for the heat applying element. The user specified thermal dose prediction properties preferably include at least one or more of overrides for any default thermal dose prediction properties, treatment site grid density; and thermal dose prediction properties not specified as default thermal dose prediction properties from the group comprised of thermal dose threshold, thermal dose prediction algorithm, maximum allowed energy for each thermal dose, thermal dose duration for each treatment site cooling time between thermal doses, and electrical properties for the heat applying element.

Patent
   RE43901
Priority
Nov 28 2000
Filed
Sep 08 2005
Issued
Jan 01 2013
Expiry
Nov 28 2020
Assg.orig
Entity
Large
23
265
all paid
0. 24. A thermal treatment system, comprising:
a heat applying element for delivering thermal doses to ablate a target mass in a patient;
a controller for controlling thermal dose properties of the heat applying element;
an imager for providing preliminary images of the target mass; and
a planner for automatically constructing a treatment plan, the treatment plan comprising a series of treatment sites that are each represented by a set of thermal dose properties,
wherein the planner automatically constructs the treatment plan based on input information including thermal dose prediction properties comprising at least one of
a set of default thermal dose prediction properties, or
a set of user specified thermal dose prediction properties.
0. 37. A method of treating a target tissue mass in a patient using a focused ultrasound system, the system comprising a transducer for delivering thermal doses of ultrasound energy to the target tissue mass, an imager for providing images of the target mass, a controller for controlling the transducer, and a planner for constructing a treatment plan, the method comprising
obtaining preliminary images of the target tissue mass; and
based on the preliminary images, constructing a treatment plan for ablating the target mass, the treatment plan comprising a series of treatment sites in the target mass that are to each receive a thermal dose of ultrasound energy from the transducer, each treatment site represented by a set of thermal dose properties to be used by the controller to control the delivery of ultrasound energy by the transducer.
0. 48. A method for treating a target tissue mass in a patient using a thermal energy treatment system, the system comprising a heat applying element for delivering thermal doses used to ablate the target mass, a controller for controlling thermal dose properties of the heat applying element, an imager for providing images of the target mass, and a planner for constructing a treatment plan, the method comprising:
receiving input information including preliminary images of the target mass; and
based on the input information, automatically constructing a treatment plan for ablating the target mass, the treatment plan comprising a series of treatment sites in the target mass that are to each receive a thermal dose from the heat applying element, each treatment site represented by a set of thermal dose properties to be used by the controller to control the delivery of the thermal doses.
1. A thermal treatment system, comprising:
a heat applying element for generating a delivering thermal dose doses used to ablate a target mass in a patient;
a controller for controlling thermal dose properties of the heat applying element;
an imager for providing preliminary images of the target mass; and
a planner for automatically constructing a treatment plan, the treatment plan comprising a series of treatment sites that are each represented by a set of thermal dose properties;
wherein the planner automatically constructs the treatment plan based on input information including one or more of:
a volume of the target mass,
a distance from a skin surface of the patient to the target mass,
a set of default thermal dose prediction properties,
a set of user specified thermal dose prediction properties,
physical properties of the heat applying elements, and
images provided by the imager.
14. A focused ultrasound system, comprising:
a transducer for generating delivering successive delivered thermal doses of ultrasound energy that results in thermal doses to ablate for ablating a target mass in a patient;
a controller for controlling thermal dose properties of the transducer;
an imager for providing preliminary images of the target mass, and for providing thermal images illustrating an actual thermal dose distribution in the patient resulting from a delivered thermal dose of ultrasound energy to the target mass; and
a planner configured for automatically constructing a treatment plan using the preliminary images, the treatment plan comprising a series of predicted thermal doses to treatment sites represented by a set of thermal dose properties used by a controller to control the transducer of the target mass;
wherein the planner further constructs a predicted thermal dose distribution illustrating the predicted thermal dose contours of each treatment site in the treatment plan;
wherein after a thermal dose is delivered to each treatment site in the treatment plan, the actual thermal dose distribution is compared to the predicted thermal dose distribution to determine remaining untreated locations within the target mass.
0. 61. A method of treating a target tissue mass in a patient using a focused ultrasound system, the system comprising a transducer for delivering thermal doses of ultrasound energy to the target tissue mass, an imager for providing images of the target mass, a controller for controlling the transducer, and a planner for constructing a treatment plan, the method comprising
obtaining preliminary images of the target tissue mass;
based on the preliminary images, automatically constructing, with the planner, a treatment plan for ablating the target mass, the treatment plan comprising a series of treatment sites in the target mass that are to each receive a thermal dose of ultrasound energy from the transducer, each treatment site represented by a set of thermal dose properties to be used by the controller to control the delivery of ultrasound energy by the transducer;
constructing a predicted thermal dose distribution illustrating the predicted thermal dose contours of the treatment sites in the treatment plan; and
delivering thermal doses of ultrasound energy to the treatment sites according to the treatment plan,
wherein the imager provides thermal images illustrating an actual thermal dose distribution in the target tissue mass resulting from a thermal dose delivered to a treatment site, and
wherein after a thermal dose is delivered to each treatment site, the actual thermal dose distribution is compared to the predicted thermal dose distribution to determine remaining untreated locations within the target mass.
2. The treatment system of claim 1, wherein the thermal dose properties translate, at least in part, to electrical and mechanical properties of the heat applying element.
3. The treatment system of claim 1, wherein the default thermal dose prediction properties are based on a type of clinical application and include at least one of:
thermal dose threshold,
thermal dose prediction algorithm,
maximum allowed energy for each thermal dose,
thermal dose duration for each treatment site,
cooling time between thermal doses, and
electrical properties for the heat applying element.
4. The treatment system of claim 1, wherein the user specified thermal close dose prediction properties include at least one of:
overrides for any default thermal dose prediction properties,
treatment site grid density, and
thermal dose prediction properties not specified as default thermal dose prediction properties selected from the group comprised consisting of thermal dose threshold, thermal dose prediction algorithm, maximum allowed energy for each thermal dose, thermal dose duration for each treatment site cooling time between thermal doses, and electrical properties for the heat applying element.
5. The treatment system of claim 1, wherein the treatment plan ensures that the entire target mass is covered by a series of thermal doses so as to obtain a composite thermal dose sufficient to ablate the entire target mass.
6. The treatment system of claim 1, wherein the thermal dose properties are automatically optimized using physiological properties as the optimization criterion.
7. The treatment system of claim 1, wherein the planner limits the thermal dose at each treatment site in order to prevent carbonization or evaporation.
8. The treatment system of claim 1, wherein the planner constructs a predicted thermal dose distribution illustrating the predicted thermal dose contours of each treatment site in the treatment plan.
9. The treatment system of claim 1, further comprising a user Interface (UI) for entering user specified thermal dose prediction properties and for editing the treatment plan once the treatment plan is constructed.
10. The treatment system of claim 1, wherein the treatment plan is constructed in three dimensions.
11. The treatment system of claim 1, further comprising a feedback imager for providing thermal images illustrating the an actual thermal dose distribution resulting from a respective thermal dose delivery at each treatment site.
12. The treatment system of claim 11, wherein the imager acts as the feedback imager.
13. The treatment system of claim 1, wherein the heat applying element applies one of the following:
ultrasound energy,
laser light energy,
RF energy,
microwave energy, and
electrical energy.
15. The focused ultrasound system of claim 14, wherein after a thermal dose is delivered to a treatment site in the treatment plan, the comparison of the actual thermal dose distribution is compared to the predicted thermal dose distribution is used to determine changes to the dosing parameters in neighboring sonication sites treatment plan for treating the remaining untreated locations.
16. The focused ultrasound system of claim 14, wherein the planner automatically evaluates the treatment plan based on the remaining untreated locations and updates, in order to ensure complete ablation of the target mass, either changes the treatment plan to ensure complete ablation of the target mass is achieved by one or more of adding treatment sites, removing treatment sites, modifying existing treatment sites, or leaving leaves the treatment plan unchanged, based on the comparison of the actual thermal dose distribution to the predicted thermal dose distribution.
17. The focused ultrasound system of claim 14, wherein a user can manually adjust the treatment plan based on the remaining untreated locations.
18. The focused ultrasound system of claim 14, wherein the preliminary images and the thermal images represent three-dimensional data.
19. The focused ultrasound system of claim 14, wherein the predicted thermal dose distribution and actual thermal dose distribution represent three-dimensional data.
20. The focused ultrasonic system of claim 14, wherein the imager further provides outlines of sensitive regions within the patient where ultrasonic waves are not allowed to pass that are sensitive to ultrasound.
21. The focused ultrasonic system of claim 20, wherein the processor planner uses the outlines in constructing the treatment plan so as to avoid exposing the sensitive regions to ultrasound.
22. The focused ultrasound system of claim 20 21, wherein the sensitive regions comprise bones, gas, and other sensitive tissues.
0. 23. The focused ultrasound system of claim 14, wherein based on the comparison of the actual thermal dose distribution to the predicted thermal dose distribution for a given treatment site, the planner adjusts the treatment plan to include delivery of an additional thermal dose to the same or substantially the same treatment site.
0. 25. The treatment system of claim 24, wherein the thermal dose properties translate, at least in part, to electrical and mechanical properties of the heat applying element.
0. 26. The treatment system of claim 24, wherein the default thermal dose prediction properties are based on a type of clinical application and include at least one of:
thermal dose threshold,
thermal dose prediction algorithm,
maximum allowed energy for each thermal dose,
thermal dose duration for each treatment site,
cooling time between thermal doses, and
electrical properties for the heat applying element.
0. 27. The treatment system of claim 24, wherein the user specified thermal dose prediction properties include at least one of:
overrides for any default thermal dose prediction properties,
treatment site grid density, and
thermal dose prediction properties not specified as default thermal dose prediction properties and selected from the group consisting of thermal dose threshold, thermal dose prediction algorithm, maximum allowed energy for each thermal dose, thermal dose duration for each treatment site cooling time between thermal doses, and electrical properties for the heat applying element.
0. 28. The treatment system of claim 24, wherein the treatment plan ensures that the entire target mass is covered by a series of thermal doses so as to obtain a composite thermal dose sufficient to ablate the entire target mass.
0. 29. The treatment system of claim 24, wherein the thermal dose properties are automatically optimized using physiological properties as the optimization criterion.
0. 30. The treatment system of claim 24, wherein the planner limits the thermal dose at each treatment site in order to prevent carbonization or evaporation.
0. 31. The treatment system of claim 24, wherein the planner constructs a predicted thermal dose distribution illustrating the predicted thermal dose contours of each treatment site in the treatment plan.
0. 32. The treatment system of claim 24, further comprising a user interface for entering user specified thermal dose prediction properties and for editing the treatment plan once the treatment plan is constructed.
0. 33. The treatment system of claim 24, wherein the treatment plan is constructed in three dimensions.
0. 34. The treatment system of claim 24, wherein the imager provides thermal images illustrating an actual thermal dose distribution resulting from a respective thermal dose delivery at each treatment site.
0. 35. The treatment system of claim 24, wherein the heat applying element applies one of the following:
ultrasound energy,
laser light energy,
RF energy,
microwave energy, and
electrical energy.
0. 36. The treatment system of claim 24, wherein the input information further includes a volume of the target tissue mass.
0. 38. The method of claim 37, further comprising constructing a predicted thermal dose distribution illustrating the predicted thermal dose contours of each treatment site in the treatment plan.
0. 39. The method of claim 37, further comprising delivering thermal doses of ultrasound energy to one or more of the treatment sites.
0. 40. The method of claim 37, wherein the imager provides thermal images illustrating an actual thermal dose distribution in the target tissue mass resulting from a thermal dose of ultrasound energy to a treatment site, the method further comprising
constructing a predicted thermal dose distribution illustrating the predicted thermal dose contours of each treatment site in the treatment plan,
delivering thermal doses of ultrasound energy to the treatment sites according to the treatment plan, and
after a thermal dose is delivered to a treatment site in the treatment plan, comparing the actual thermal dose distribution to the predicted thermal dose distribution for the treatment site.
0. 41. The method of claim 40, further comprising, based on the comparison of the actual thermal dose distribution to the predicted thermal dose distribution, selectively changing the treatment plan by one or more of adding treatment sites, removing treatment sites, and modifying treatment sites, to ensure complete ablation of the target mass.
0. 42. The method of claim 40, further comprising, based on the comparison of the actual thermal dose distribution to the predicted thermal dose distribution, delivering an additional thermal dose of ultrasound energy to the same or substantially the same treatment site.
0. 43. The method of claim 37, further comprising manually adjusting the treatment plan.
0. 44. The method of claim 37, further comprising:
identifying in images used to construct the treatment plan outlines of regions within the patient that are sensitive to the application of ultrasound, and
constructing the treatment plan so as to avoid exposure of the sensitive regions to ultrasound energy delivered by the transducer.
0. 45. The method of claim 37, wherein the thermal dose properties translate, at least in part, to electrical and mechanical properties of the transducer.
0. 46. The method of claim 37, wherein the treatment plan ensures that the entire target mass is covered by a series of thermal doses of ultrasound energy so as to obtain a composite thermal dose sufficient to ablate the entire target mass.
0. 47. The method of claim 37, further comprising optimizing the thermal dose properties based on physiological properties as optimization criterion.
0. 49. The method of claim 48, further comprising automatically constructing a predicted thermal dose distribution illustrating the predicted thermal dose contours of each treatment site in the treatment plan.
0. 50. The method of claim 48, further comprising delivering thermal doses from the heat applying element to one or more of the treatment sites.
0. 51. The method of claim 48, wherein the imager provides thermal images illustrating an actual thermal dose distribution in the target tissue mass resulting from a thermal dose delivered to a treatment site, the method further comprising
constructing a predicted thermal dose distribution illustrating the predicted thermal dose contours of each treatment site in the treatment plan,
delivering thermal doses to the treatment sites according to the treatment plan, and
after a thermal dose is delivered to a treatment site in the treatment plan, comparing the actual thermal dose distribution to the predicted thermal dose distribution for the treatment site.
0. 52. The method of claim 51, further comprising, based on the comparison of the actual thermal dose distribution to the predicted thermal dose distribution, changing the treatment plan by one or more of adding treatment sites, removing treatment sites, and modifying treatment sites, to ensure complete ablation of the target mass.
0. 53. The method of claim 51, further comprising, based on the comparison of the actual thermal dose distribution to the predicted thermal dose distribution, leaving the treatment plan unchanged in order to ensure complete ablation of the target mass.
0. 54. The method of claim 51, further comprising, based on the comparison of the actual thermal dose distribution to the predicted thermal dose distribution, delivering an additional thermal dose to the same or substantially the same treatment site.
0. 55. The method of claim 48, further comprising manually adjusting the treatment plan.
0. 56. The method of claim 48, wherein the thermal dose properties translate, at least in part, to electrical and mechanical properties of the heat applying element.
0. 57. The method of claim 48, wherein the treatment plan ensures that the entire target mass is covered by a series of thermal doses so as to obtain a composite thermal dose sufficient to ablate the entire target mass.
0. 58. The method of claim 48, further comprising optimizing the thermal dose properties based on physiological properties as optimization criterion.
0. 59. The method of claim 48, wherein the input information further includes one or more of the group consisting of:
a volume of the target mass,
default thermal dose prediction properties, and
user specified thermal dose prediction properties.
0. 60. The method of claim 53, wherein the heat applying element applies one of the following:
ultrasound energy,
laser light energy,
RF energy,
microwave energy, and
electrical energy.
0. 62. The method of claim 61, wherein the comparison of the actual thermal dose distribution to the predicted thermal dose distribution is used to determine changes to the treatment plan for treating the remaining untreated locations.
0. 63. The method of claim 61, wherein the planner automatically evaluates the treatment plan based on the remaining untreated locations and, in order to ensure complete ablation of the target mass, either changes the treatment plan by one or more of adding treatment sites, removing treatment sites, and modifying existing treatment sites, or leaves the treatment plan unchanged.
0. 64. The method of claim 61, further comprising manually adjusting the treatment plan based on the remaining untreated locations.
0. 65. The method of claim 61, wherein the preliminary images and the thermal images represent three-dimensional data.
0. 66. The method of claim 61, wherein the predicted thermal dose distribution and actual thermal dose distribution represent three-dimensional data.
0. 67. The method of claim 61, wherein the imager further provides outlines of regions within the patient that are sensitive to ultrasound, and wherein the planner uses the outlines in constructing the treatment plan so as to avoid exposing the sensitive regions to ultrasound.

This application is a reissue of U.S. patent application Ser. No. 09/724,670, filed Nov. 28, 2000, issued as U.S. Pat. No. 6,618,620.

The present invention relates generally to thermal treatment systems, and more particularly to a method and apparatus for controlling thermal dosing in a thermal treatment system.

Thermal energy, such as generated by high intensity focused ultrasonic waves (acoustic waves with a frequency greater than about 20 kilohertz), may be used to therapeutically treat internal tissue regions within a patient. For example, ultrasonic waves may be used to ablate tumors, thereby obviating the need for invasive surgery. For this purpose, piezoelectric transducers driven by electric signals to produce ultrasonic energy have been suggested that may be placed external to the patient but in close proximity to the tissue to be ablated. The transducer is geometrically shaped and positioned such that the ultrasonic energy is focused at a “focal zone” corresponding to a target tissue region within the patient, heating the target tissue region until the tissue is coagulated. The transducer may be sequentially focused and activated at a number of focal zones in close proximity to one another. This series of “sonications” is used to cause coagulation necrosis of an entire tissue structure, such as a tumor, of a desired size and shape.

In such focused ultrasound systems, the transducer is preferably geometrically shaped and positioned so that the ultrasonic energy is focused at a “focal zone” corresponding to the target tissue region, heating the region until the tissue is necrosed. The transducer may be sequentially focused and activated at a number of focal zones in close proximity to one another. For example, this series of “sonications” may be used to cause coagulation necrosis of an entire tissue structure, such as a tumor, of a desired size and shape.

By way of illustration, FIG. 1A depicts a phased array transducer 10 having a “spherical cap” shape. The transducer 10 includes a plurality of concentric rings 12 disposed on a curved surface having a radius of curvature defining a portion of a sphere. The concentric rings 12 generally have equal surface areas and may also be divided circumferentially 14 into a plurality of curved transducer sectors, or elements 16, creating a “tiling” of the face of the transducer 10. The transducer elements 16 are constructed of a piezoelectric material such that, upon being driven with a sinus wave near the resonant frequency of the piezoelectric material, the elements 16 vibrate according to the phase and amplitude of the exciting sinus wave, thereby creating the desired ultrasonic wave energy.

As illustrated in FIG. 1B, the phase shift and amplitude of the respective sinus “drive signal” for each transducer element 16 is individually controlled so as to sum the emitted ultrasonic wave energy 18 at a focal zone 20 having a desired mode of focused planar and volumetric pattern. This is accomplished by coordinating the signal phase of the respective transducer elements 16 in such a manner that they constructively interfere at specific locations, and destructively cancel at other locations. For example, if each of the elements 16 are driven with drive signals that are in phase with one another, (known as “mode 0”), the emitted ultrasonic wave energy 18 are focused at a relatively narrow focal zone. Alternatively, the elements 16 may be driven with respective drive signals that are in a predetermined shifted-phase relationship with one another (referred to in U.S. Pat. No. 4,865,042 to Umemura et al. as “mode n”). This results in a focal zone that includes a plurality of 2n zones disposed about an annulus, i.e., generally defining an annular shape, creating a wider focus that causes necrosis of a larger tissue region within a focal plane intersecting the focal zone. Multiple shapes of the focal spot can be created by controlling the relative phases and amplitudes of the emmitted energy from the array, including steering and scanning of the beam, enabling electronic control of the focused beam to cover and treat multiple of spots in the defined zone of a defined tumor inside the body.

More advanced techniques for obtaining specific focal distances and shapes are disclosed in U.S. patent application Ser. No. 09/626,176, filed Jul. 27, 2000, entitled “Systems and Methods for Controlling Distribution of Acoustic Energy Around a Focal Point Using a Focused Ultrasound System;” U.S. patent application Ser. No. 09/556,095, filed Apr. 21, 2000, entitled “Systems and Methods for Reducing Secondary Hot Spots in a Phased Array Focused Ultrasound System;” and U.S. patent application Ser. No. 09/557,078, filed Apr. 21, 2000, entitled “Systems and Methods for Creating Longer Necrosed Volumes Using a Phased Array Focused Ultrasound System.” The foregoing (commonly assigned) patent applications, along with U.S. Pat. No. 4,865,042, are all hereby incorporated by reference for all they teach and disclose.

It is significant to implementing these focal positioning and shaping techniques to provide a transducer control system that allows the phase of each transducer element to be independently controlled. To provide for precise positioning and dynamic movement and reshaping of the focal zone, it is desirable to be able to alter the phase and/or amplitude of the individual elements relatively fast, e.g., in the μ second range, to allow switching between focal points or modes of operation. As taught in the above-incorporated U.S. patent application Ser. No. 09/556,095, it is also desirable to be able to rapidly change the drive signal frequency of one or more elements.

Further, in a MRI-guided focused ultrasound system, it is desirable to be able to drive the ultrasound transducer array without creating electrical harmonics, noise, or fields that interfere with the ultra-sensitive receiver signals that create the images. A system for individually controlling and dynamically changing the phase and amplitude of each transducer element drive signal in phased array focused ultrasound transducer in a manner which does not interfere with the imaging system is taught in commonly assigned U.S. patent application Ser. No. [not-yet-assigned; Lyon & Lyon Attorney Docket No. 254/189, entitled “Systems and Methods for Controlling a Phased Array Focussed Ultrasound System,”], which was filed on the same date herewith and which is hereby incorporated by reference for all it teaches and discloses.

Notably, after the delivery of a thermal dose, e.g., ultrasound sonication, a cooling period is required to avoid harmful and painful heat build up in healthy tissue adjacent a target tissue structure. This cooling period may be significantly longer than the thermal dosing period. Since a large number of sonications may be required in order to fully ablate the target tissue site, the overall time required can be significant. If the procedure is MRI-guided, this means that the patient must remain motionless in a MRI machine for a significant period of time, which can be very stressful. At the same time, it may be critical that the entire target tissue structure be ablated (such as, e.g., in the case of a malignant cancer tumor), and that the procedure not take any short cuts just in the name of patient comfort.

Accordingly, it would be desirable to provide systems and methods for treating a tissue region using thermal energy, such as focused ultrasound energy, wherein the thermal dosing is applied in a more efficient and effective manner.

In accordance with a first aspect of the invention, a thermal treatment system is provided, the system including a heat applying element for generating a thermal dose used to ablate a target mass in a patient, a controller for controlling thermal dose properties of the heat applying element, an imager for providing preliminary images of the target mass and thermal images during the treatment, and a planner for automatically constructing a treatment plan, comprising a series of treatment sites that are each represented by a set of thermal dose properties. By way of non-limiting example only, the heat applying element may apply any of ultrasound energy, laser light energy, radio frequency (RF) energy, microwave energy, or electrical energy.

In a preferred embodiment, the planner automatically constructs the treatment plan based on input information including one or more of a volume of the target mass, a distance from a skin surface of the patient to the target mass, a set of default thermal dose prediction properties, a set of user specified thermal dose prediction properties, physical properties of the heat applying elements, and images provided by the imager. The default thermal dose prediction properties are preferably based on a type of clinical application and include at least one of thermal dose threshold, thermal dose prediction algorithm, maximum allowed energy for each thermal dose, thermal dose duration for each treatment site, cooling time between thermal doses, and electrical properties for the heat applying element. The user specified thermal dose prediction properties preferably include at least one or more of overrides for any default thermal dose prediction properties, treatment site grid density; and thermal dose prediction properties not specified as default thermal dose prediction properties from the group comprised of thermal dose threshold, thermal dose prediction algorithm, maximum allowed energy for each thermal dose, thermal dose duration for each treatment site cooling time between thermal doses, and electrical properties for the heat applying element.

Preferably, the treatment plan ensures that the entire target mass is covered by a series of thermal doses so as to obtain a composite thermal dose sufficient to ablate the entire target mass, and the thermal dose properties are automatically optimized using physiological properties as the optimization criterion. Preferably, the planner limits the thermal dose at each treatment site in order to prevent evaporation or carbonization.

In a preferred embodiment, the planner constructs a predicted thermal dose distribution in three dimensions, illustrating the predicted thermal dose threshold contours of each treatment site in the treatment plan. A User Interface (UI) may also be provided for entering user specified thermal dose prediction properties and for editing the treatment plan once the treatment plan is constructed. A feedback imager for providing thermal images may also be provided, wherein the thermal images illustrate the actual thermal dose distribution resulting at each treatment site. In one embodiment, the imager acts as the feedback imager.

In accordance with another aspect of the invention, a focused ultrasound system is provided, including a transducer for generating ultrasound energy that results in thermal doses used to ablate a target mass in a patient, a controller for controlling thermal dose properties of the transducer, an imager for providing preliminary images of the target, and for providing thermal images illustrating an actual thermal dose distribution in the patient, and a planner for automatically constructing a treatment plan using the preliminary images, the treatment plan comprising a series of treatment sites represented by a set of thermal dose properties used by the controller to control the transducer.

The planner preferably constructs a predicted thermal dose distribution illustrating the predicted thermal dose contours of each treatment site in the treatment plan, wherein after a thermal dose is delivered to a treatment site in the treatment plan, the actual thermal dose distribution is compared to the predicted thermal dose distribution to determine remaining untreated locations within the target mass. The planner preferably automatically evaluates the treatment plan based on the remaining untreated locations and will update the treatment plan to ensure complete ablation of the target mass is achieved by adding treatment sites, removing treatment sites, modifying existing treatment sites, or leaving the treatment plan unchanged. In some embodiments, a user can manually adjust the treatment plan based on the remaining untreated locations.

Preferably, the imager provides outlines of sensitive regions within the patient where ultrasonic waves are not allowed to pass, wherein the processor uses the outlines in constructing the treatment plan so as to avoid exposing the sensitive regions to ultrasound.

In accordance with still another aspect of the invention, a method of controlling thermal dosing in a thermal treatment system is provided, which includes selecting an appropriate clinical application protocol, the selected application protocol having associated with it certain default thermal dosing properties; retrieving relevant magnetic resonant images for thermal dose planning; tracing a target mass on the images; entering user specified thermal dosing properties and selectively modifying the default thermal dosing properties; and automatically constructing a treatment plan representing thermal doses to be applied to treatment sites, the treatment plan based on the default thermal dosing properties and the user specified thermal dosing properties.

In preferred implementations, tracing the target mass can be done manually or automatically, and may include evaluating the target mass to ensure that obstacles including bones, gas, or other sensitive tissue will not interfere with the thermal doses and repositioning a patient or a heat applying element in order to bypass any such obstacles. Preferably, the treatment plan ensures that a target mass receives a composite thermal dose sufficient to ablate the target mass, wherein automatically constructing the treatment plan includes predicting and displaying a predicted thermal dose distribution. Preferably, automatically constructing the treatment plan further includes calculating limits for each thermal dose to be applied to each treatment site in order to prevent evaporation or carbonation.

In a preferred implementation, the treatment plan may be manually edited, including at least one of adding treatment sites, deleting treatment sites, changing the location of treatment sites, changing thermal dosing properties, and reconstructing the entire treatment plan with new thermal dosing properties.

In one implementation, the method includes applying a low energy thermal dose at a predetermined spot within the target mass in order to verify proper registration, and evaluating said predetermined spot and adjusting and/or re-verifying if necessary. In a following step, the low energy thermal dose could be extended to a full dose sonication that will be evaluated to assess the thermal dosing parameters as a scaling factor for the full treatment.

Other aspects and features of the invention will become apparent hereinafter.

The drawings illustrate both the design and utility of preferred embodiments of the invention, in which similar elements in different embodiments are referred to by the same reference numbers for purposes of ease in illustration, and wherein:

FIG. 1A is a top view of an exemplary spherical cap transducer comprising a plurality of transducer elements to be driven in a phased array as part of a focussed ultrasound system.

FIG. 1B is a partially cut-away side view of the transducer of FIG. 1A, illustrating the concentrated emission of focused ultrasonic energy in a targeted focal region.

FIG. 2 is simplified schematic block diagram of a thermal treatment system for providing thermal energy dosing of a target tissue region in a patient.

FIG. 3 is a cross-sectional view of an ultrasonic transducer and target tissue mass to be treated in a preferred embodiment of the system of FIG. 2.

FIG. 4 is a cross-sectional view of a target tissue mass, illustrating a series of planned sonication areas.

FIG. 5 is a preferred process flow diagram for constructing a three-dimensional treatment plan using the system of FIG. 2.

FIG. 6 is a simplified schematic block diagram of an alternate thermal treatment system comprising a feedback image generator.

FIGS. 7A and 7B are two-dimensional representations of a target sonication areas, illustrating instances in which the actual thermal ablation is either greater than (FIG. 7A), or less than (FIG. 7B), the predicted amount.

FIG. 8 illustrates a comparison of actual versus predicted thermal doses for an entire target tissue region constructed by the system of FIG. 6 using images from the feedback image generator.

FIG. 9 illustrates a preferred method of controlling thermal dosing in a thermal treatment system.

FIG. 10A illustrates a two dimensional pixel representation of a predicted thermal dose to be applied to a target tissue region.

FIG. 10B illustrates a two dimensional pixel representation of an actual thermal dose resulting from a thermal treatment intended to result in the predicted thermal dose of FIG. 10A.

FIG. 10C illustrates a two dimensional pixel representation of a remaining untreated target tissue region derived by subtracting the pixel representation of FIG. 10B from the pixel representation of FIG. 10A.

FIG. 11 illustrates a preferred method for updating a thermal treatment plan.

The invention will now be illustrated by examples that use an ultrasound transducer as the means of delivering energy to a target mass. It will be apparent to those skilled in the art, however, that other energy delivery vehicles can be used. For example, the invention is equally applicable to systems that use laser light energy, radio frequency (RF) energy, microwave energy, or electrical energy converted to heat, as in an ohmic heating coil or contact. Therefore, the following preferred embodiments should not be considered to limit the invention to an ultrasound system.

FIG. 2 illustrates a thermal treatment system 100 in accordance with one embodiment of the invention. Thermal treatment system 100 uses a heat applying element 102 to focus an energy beam 112 on a target mass 104, which is typically a tumor within a patient 116. In one preferred implementation, the thermal treatment system 100 is a focused ultrasound system and the heat applying element 102 is a transducer that delivers an ultrasound beam. In this embodiment, the transducer 102 may consist of a spherical cap transducer such as that disclosed in the above-incorporated Umemura patent. It will be appreciated by those skilled in the art that a variety of geometric designs for transducer 102 may be employed. Additionally, alternate embodiments of system 100 will use focused radiators, acoustic lenses, or acoustic reflectors in order to achieve optimal focus of beam 112.

Ultrasound is a vibrational energy that is propagated as a mechanical wave through a target medium. In system 100, transducer 102 generates the mechanical wave by converting an electronic drive signal into mechanical motion. The frequency of the mechanical wave, and therefore ultrasound beam 112, is equal to the frequency of the drive signal. The ultrasound frequency spectrum begins at 20 Khz and typical implementations of system 100 employ frequencies in the range from 0.5 to 10 Mhz. Transducer 102 also converts the electronic drive signal power into acoustic power in ultrasound beam 112. Ultrasound beam 112 raises the temperature of target mass 104 by transferring this power as heat to target mass 104. Ultrasound beam 112 is focused on the target mass 104 in order to raise the temperature of the target mass tissue to a point where the tissue is destroyed. The heat distribution within the tissue is controlled by the intensity distribution in the focal spot of beam 112, the intensity distribution, in turn, is shaped by the interaction of the beam with the tissue and the frequency, duration, and power of beam 112, which are directly related to the frequency, duration, and power of the electronic drive signal.

As seen in FIG. 3, the transducer 102 focuses beam 112 on a target tissue mass 104, which is within a patient 116 some distance from skin surface 202. The distance from skin surface 202 to target mass 104 is the near field 204, which contains healthy tissue. It is important that tissue in near field 204 is not damaged by beam 112. Energy zone 206 is the target zone for beam 112, wherein energy is transferred as heat to the tissue of the target mass 104. Energy zone 206 is divided into several cross sections of varying depth. Varying the frequency of the electric signal driving transducer 102 can target particular cross sections within energy zone 206.

Two proportionalities illustrate this point: (1) d is proportional to k1(v/f)(R/2a); and (2) l is proportional to k2(v/f) (R/2a)2. In (1), d represents the diameter of the focal spot of beam 112. R represents the radius of curvature, and 2a represents the diameter, respectively, of transducer 102. Therefore, the physical parameters associated with transducer 102 are important parameters, as well. In (2), l represents the axial length of the focus of beam 112. Different cross sections can be targeted by changing the frequency f, which will vary the focal length l. In both (1) and (2), v is the speed of sound in body tissue and is approximately 1540 m/s.

As can be seen, the same parameters that play an important role in determining the focal length l, also play an important role in determining the focal spot diameter d. Because the focal spot will typically be many times smaller than transducer 102, the acoustic intensity will be many times higher in the focal spot as compared to the intensity at the transducer. In some implementations, the focal spot intensity can be hundreds or even thousands of times higher than the transducer intensity. The frequency f also effects the intensity distribution within energy zone 206: The higher the frequency, the tighter the distribution, which is beneficial in terms of not heating near field 204.

The duration of a sonication determines how much heat will actually be transferred to the target mass tissue at the focal spot. For a given signal power and focal spot diameter, a longer duration results in more heat transfer and, therefore, a higher temperature. Thermal conduction and blood flow, however, make the actual temperature distribution within the tissue unpredictable for longer sonication duration. As a result, typical implementations use duration of only a few seconds. In focused ultrasound systems, care must also be taken not to raise the temperature at the focal point too high. A temperature of 100° C. will cause water in the tissue to boil forming gas in the path of beam 112. The gas blocks the propagation of beam 112, which significantly impacts the performance of system 100.

Controller 106 controls the mechanical and electrical properties of transducer 102. For example, controller 106 controls electrical properties such as the frequency, duration, and amplitude of the electronic drive signal and mechanical properties such as the position of transducer 102. By controlling the position of transducer 102, the position of the focal spot within target mass 116 can be controlled. In one embodiment, controller 106 controls the x-position, z-position, the pitch, and the roll of transducer 102. A preferred mechanical positioning system for controlling the physical position of the transducer is taught in commonly assigned U.S. patent application Ser. No. 09/628,964, entitled “Mechanical Positioner for MRI Guided Ultrasound Therapy System,” which is hereby incorporated by reference for all it teaches and discloses.

In one implementation, electromechanical drives under the control of controller 106 are used to control these positional aspects. It will be apparent to those skilled in the art that other implementations may employ other means to position transducer 102 including hydraulics, gears, motors, servos, etc. Additionally, it must be remembered that controlling the electrical properties, mainly frequency f and phase of transducer 102 controls the position of the focal spot along the y-axis of transducer 102 and the dimensions of the focal volume. Controller 106 uses properties provided by planner 108 to control the mechanical and electrical properties of transducer 102.

Planner 108 automatically constructs a treatment plan, which consists of a series of treatment site represented by thermal dose properties. The purpose of the treatment plan is to ensure complete ablation of target mass 104 by planning a series of sonications that will apply a series of thermal doses at various points within target mass 104, resulting in a composite thermal dose sufficient to ablate the entire mass.

For example, the plan will include the frequency, duration, and power of the sonication and the position and mode of the focal spot for each treatment site in series of treatment sites. The mode of the focal spot refers to the fact that the focal spot can be of varying dimensions. Typically, there will be a range of focal modes from small to large with several intermediate modes in between. The actual size of the focal spot will vary, however, as a function of the focal distance (l), the frequency and focal spot dispersion mode. Therefore, planner 108 must take the mode and focal spot size variation into account when planning the position of the focal spot for a treatment site. The treatment plan is then passed to controller 106 in the relevant format to allow controller 106 to perform its tasks.

In order to construct the treatment plan, planner 108 uses input from User Interface (UI) 110 and imager 114. For example, in one implementation, a user specifies the clinical application protocol, i.e., breast, pelvis, eye, prostate, etc., via UI 110. Selection of the clinical application protocol may control at least some of the default thermal dose prediction properties such as thermal dose threshold, thermal dose prediction algorithm, maximum allowed energy for each thermal dose, thermal dose duration for each treatment site, cooling time between thermal doses, and electrical properties for the heat applying element.

In other implementations, some or all of these properties are input through UI 110 as user specified thermal dose prediction properties. Other properties that may be input as user specified thermal dose prediction properties are the sonication grid density (how much the sonications should overlap) and the physical parameters of transducer 102. The latter two properties may also be defined as default parameters in certain implementations.

Additionally, a user may edit any of the default parameters via UI 110. In one implementation, UI 110 comprises a Graphical User Interface (GUI): A user employs a mouse or touch screen to navigate through menus or choices as displayed on a display device in order to make the appropriate selections and supply the required information.

To further aid planner 108 in constructing the treatment plan, imager 114 supplies images of target mass 104 that can be used to determine volume, position, and distance from skin surface 202. In a typical implementation, imager 114 is a Magnetic Resonance Imaging (MRI) device and, in one implementation, the images provided are three-dimensional images of target mass 104. Once planner 108 receives the input from UI 110 and the images from imager 114, planner 108 automatically constructs the treatment plan.

As illustrated in FIG. 4, the goal of the treatment plan is to completely cover a target tissue mass 300 with a series of sonications 304 so that the entire target mass is fully ablated. In one implementation, once the treatment plan is constructed a user may, if required, edit the plan by using UI 110. In one implementation, planner 108 will also produce a predicted thermal dose distribution. This distribution is similar to the distribution illustrated in FIG. 4, wherein the predicted thermal doses 304 are mapped onto images of target mass 104 provided by imager 114. In one implementation, the distribution is a three-dimensional distribution. Additionally an algorithm is included in planner 108 that limits the peak temperature of the focal zone so as to prevent evaporation. The algorithm is referred to as the dose predictor.

In one implementation, the treatment plan is a three-dimensional treatment plan. FIG. 5 illustrates one preferred process flow diagram for constructing a three-dimensional treatment plan, using three-dimensional images of target mass 104 and a three-dimensional predicted thermal dose distribution 300. The ability of focusing at different focal lengths (l) leads to variable focal spots and variable lesion sizes in target mass 104 as a function of (y), the transducer axis. Therefore, as a result of the process illustrated in FIG. 5, planner 108 finds a minimum number of overlapping cross-sectional treatment layers required to ablate a portion of target mass 104 extending from ynear to yfar.

Planner 108 will also predict the lesion size in the cross-sectional layer and will provide the maximal allowed energy in each layer, taking into account the maximum allowed temperature rise. The energy or power will be normalized among different layers, such that the maximal temperature at the focus remains approximately constant throughout the treatment zone 206.

Constructing the three-dimensional treatment plan begins in step 402 with obtaining diagnostic quality images of the target mass. For example, the diagnostic quality images may be the preliminary images supplied by an imager such as imager 114. In step 404, planner 108 uses the diagnostic images to define the treatment region. Then, in step 406, a line y=[ynear:yfar] is defined such that (y) cuts through target zone 206 perpendicular to transducer along the transducer axis from the nearest point within target mass 104 (ynear) to the furthest point (yfar). Line (y) will be the axis along which the treatment layers will be defined.

Once (y) is defined planner 108 will perform a dose prediction in step 408 using the maximal power required for small and large spot sizes at (yfar). In step 410, planner 108 determines if the resulting maximal temperature exceeds the allowed limit. It should be noted that properties such as the maximal power and the maximal temperature limit may be supplied as default thermal dose prediction properties or may be supplied as user supplied thermal dose prediction properties. If the resulting maximal temperature does exceed the allowable limit, the power is scaled down linearly in step 412 until the temperature elevation is within the allowable limit.

The small and large focal modes may correspond to modes 0 and 4, respectively, with additional modes 1, 2 and 3 falling between modes 0 and 4. Therefore, in step 414, planner 108 predicts the maximal power for the intermediate modes 1, 2 and 3, from the scaled max powers at modes 0 and 4. Thus, in step 416, if there are further modes, planner 108 reverts to step 408 and predicts the maximal power for these modes. If it is the last mode for (yfar) then planner 108 uses the same scaled max power, as in step 418, to find the corresponding maximal powers for each focal mode at (ynear). Then in step 420, planner 108 finds the maximal temperature elevation and lesion size for the appropriate mode and the required maximal power at a point (yl), such that ynear<yl<yfar. Preferably, (yl) is close to (ynear). For example, in one implementation, yl=ynear+25 mm. If the temperature elevation at (yl) exceeds the allowable limit as determined in step 422, then in step 424 the power is scaled down until the temperature elevation is within the limit, and then planner 108 determines the resulting lesion size at (yl).

Using an overlap criterion with respect to the (ynear) boundary, which may be provided via a sonication grid density, the first treatment is placed. The treatment will actually be a three-dimensional layer or slice. Then, in step 428, using an inter-layer overlap criterion, an auxiliary treatment slice is placed on top of the previous treatment layer using the same height for the second slice as for the first slice. In step 430, planner 108 determines if more layers are needed to reach (yfar). If more layers are needed, then the process reverts to step 418, and (yl) replaces (ynear) (step 432) in the algorithm.

Once the last treatment layer is reached, planner 108 will determine if the layer extends beyond the target limit (yfar). If the layer does extend too far, then the overlap criterion should be used with the outer limit (yfar) as a boundary instead of the previous layer. Using (yfar) in the overlap criterion may cause overdose but will not damage healthy tissue outside target mass 104.

In one implementation, the thermal dose properties are automatically optimized using physiological parameters as the optimization criterion in one implementation mechanical tissue parameters like compressibility, stiffens and scatter are used.

Referring to FIG. 6, a thermal treatment system 500, similar to system 100 of FIG. 2, includes an online feedback imager 502. In practice, the actual thermal dose delivered with a particular sonication is not the same as the thermal dose predicted by planner 108. As mentioned previously, absorption coefficient blood flow, uneven heat conduction, different rates of conduction for different tissue masses, tissue induced beam aberration and variances in system tolerances make it difficult to accurately predict thermal dosages. Moreover, the actual focal spot dimensions are variable as a function of focal distance (l) and of focal spot dispersion, making accurate thermal dosing predictions even more difficult.

As illustrated in FIGS. 7A-B, the actual thermal dose 606 will often not ablate the predicted amount of tissue. In particular, two situations can occur. First, as illustrated by comparison 602 in FIG. 7A, actual thermal dose 606 may be larger than predicted thermal dose 608. In this case there will be an overlap of ablated tissue 610. The second situation is illustrated by comparison 604 in FIG. 7B. In this case, actual thermal dose 606 is smaller than predicted thermal dose 608. Therefore, there is an area 612 of non-ablated tissue remaining after sonication.

The online feedback imager 502 provides real-time temperature sensitive magnetic resonance images of target mass 104 after some or all of the sonications. The planner 108 uses the images from the feedback imager 502 to construct an actual thermal dose distribution 600 comparing the actual composite thermal dose to the predicted composite thermal dose as illustrated in FIG. 8. In particular, thermal dose distribution 600 illustrates a comparison of the actual versus predicted thermal dose for each or some of the sonications. As can be seen, overlapping areas 610 and non-ablated areas 612 will result in over- or under-dosing as the treatment plan is implemented and thermal doses are applied to different treatment sites 614 within target mass 104.

In one implementation, the images provided by feedback imager 502 and the updated thermal dose distributions 600 represent three-dimensional data. Planner 108 uses thermal dose distribution 600 to automatically adjust the treatment plan, in real-time, after each sonication or uses the thermal dose distribution 600 in some of the points to adjust for the neighboring points. Planner 108 can adjust the treatment plan by adding treatment sites, removing treatment sites, or continuing to the next treatment site. Additionally, the thermal dose properties of some or all remaining treatment sites may automatically be adjusted by planner 108 based on real-time feedback from feedback imager 502.

As mentioned, planner 108 reformulates the treatment plan automatically after each thermal dose or after some of the sonication points, thus ensuring that target mass 104 is completely ablated in an efficient and effective manner. In addition, the feedback provided by online feedback imager 502 might be used to manually adjust the treatment plan or to override the changes made by planner 108. It should be noted that in one example embodiment, imager 114 also functions as feedback imager 502.

A preferred method of controlling thermal dosing in a thermal treatment system (e.g., systems 100 and 500) is illustrated in FIG. 9. Initially, a user selects an appropriate clinical application protocol in step 702. For example, a user may use an interface such as UI 110 to select the clinical application protocol. In one embodiment, selecting the clinical application protocol controls a set of default thermal dose prediction parameters. After the clinical application is selected, relevant magnetic resonant images of a target mass are retrieved in step 704. For example, the images may be retrieved by a means such as imager 114. In step 706, the images are used to define a target region such as a treatment slice as discussed previously. In one embodiment, defining the target region involves manually or automatically tracing the target mass onto the images retrieved in step 704. In one implementation, the target mass is traced in three dimensions onto three-dimensional images for three-dimensional treatment planning. In another embodiment that uses ultrasound, the operator is allowed to account for obstacles such as bones, gas, or other sensitive tissue and plan accordingly to ensure that the ultrasound beam will not pass through these obstacles. Based on this planning, a patient may be repositioned or the transducer may be repositioned and/or tilted in order to avoid the obstacles.

In step 708, the user may enter additional thermal dose prediction properties or modify any default thermal dose prediction properties already selected. For example, these additional properties may be entered via UI 110. Then in step 710, a treatment plan is automatically constructed based on the properties obtained in the previous steps. The purpose of the treatment plan is to ensure a proper composite thermal dose sufficient to ablate the target mass by applying a series of thermal doses to a series of treatment sites, automatically accounting for variations in the focal spot sizes and in the thermal dose actually delivered to the treatment site.

The treatment plan may, for example, be automatically constructed by a planning means such as planner 108. In one embodiment, automatically constructing the treatment plan includes constructing an expected thermal dose distribution showing the predicted thermal dose at each treatment site. This thermal dose distribution may represent a three-dimensional distribution, and, in such an implementation, constructing the treatment plan may follow the steps illustrated in FIG. 5, and described above. In another embodiment, constructing the treatment plan further comprises calculating limits for the ultrasonic energy associated with each sonication so as to prevent evaporation.

In step 712, the treatment plan is edited by manual input. For example, UI 110 may be used to edit the treatment plan. In one embodiment, editing the plan may include adding treatment sites, deleting treatment sites, changing the location of some or all of the treatment sites, changing other thermal dose properties for some or all treatment sites, or reconstructing the entire plan. As illustrated by step 720, if the plan is edited, then the process reverts to step 708 and continues from there. Once the plan is set, then verification step 714 is performed. Verification is required to ensure that treatment system 100 is properly registered with regard to the position of the focal spot relative to patient 116 and target mass 104. In one embodiment, verification comprises performing a low energy thermal dose at a predefined spot within said target mass in order to verify proper registration. In a following step, the verification could be repeated at full energy level to calibrate the dosing parameters. As illustrated by step 722, re-verification may be required depending on the result of step 714. In this case, the process reverts back to step 714 and verification is performed again. On the other hand, mechanical properties, such as position, relating to transducer 102 may need to be changed (step 720) and, therefore, the process reverts to step 708.

Once the verification is complete, the treatment plan is implemented in step 716. In one embodiment, this step comprises capturing temperature sensitive image sequences of the target mass as each step of the plan is being implemented. These images will illustrate the actual thermal dose distribution resulting from each successive thermal dose. An online feedback imager 502 may, for example, provide the temperature sensitive images that are used to construct the actual thermal dose distribution. In step 718, the actual thermal dose distribution is compared with the predicted thermal dose distribution in order to determine how closely the actual treatments are tracking the treatment plan. Then in step 724, it is determined if the treatment can proceed to the next step (repeat step 716), or if changes must be made to the treatment plan. (step 720). The changes may be accomplished manually or automatically and may comprise adding treatment sites, deleting treatment sites, repeating treatment sites, or modifying specific thermal dose properties for some or all of the treatment sites.

There are several methods that are used to change or update the treatment plan. For example, at the end of each thermal dose, there may be regions within the target layer that are not covered by accumulated dose contours. These untreated areas are separated into individual regions. Each of these regions is then sent through the process, beginning with step 708, resulting in an updated treatment plan constructed to treat the remaining regions. The process will repeat until there are no more untreated regions.

In order to accomplish the tracking of untreated regions, each treatment region may be maintained as a two-dimensional linked list of pixel ranges sorted by (y) and then (x) coordinates as illustrated in FIGS. 10A-C. As can be seen in FIG. 10A, the treatment region is a continuous region 802 represented by the lighter pixels. The pixel distribution is then represented by the data structure 804. This type of representation is called “run-length encoding.” The data structure 804 contains linked lists 806 by row indicating the pixels that contain treatment region 802. Thus, for row 1, list element 806a indicates that the pixel range from 1 to 2 contains a portion of treatment region 802, 806b indicates that the pixel range from 7 to 7 contains a portion of treatment region 802, and 806c indicates that the pixel range from 11 to 11 contains a portion of treatment region 802. It can also be seen that rows 0 and 5 do not contain any portion of treatment region 802; therefore, these rows in data structure 804 do not contain any pixel ranges.

Once a thermal dose is applied, the area of the target mass that is destroyed (the treated region) is represented in the same fashion as the untreated region shown in FIG. 10A. The treated region (FIG. 10B) is subtracted from the untreated region in order to define the remaining untreated region within treatment region 802. These areas can then be sent back to the planning stage (step 720) and the treatment plan can be updated.

Subtraction of the run-lengths representing untreated region and the treated-region follows the following rules:

For run-length segments [a,b] and [c,d],

[a,b] − [c,d] = c > b or d < a [a,b] (1)
c <= a and d >= b 0 (2)
c > a and d >= b [a, c − 1] (3)
c <= a and d < b [d + 1, b] (4)
c > a and d < b [a, c − 1] and [d + 1, b] (5)

The subtraction, therefore, of two regions involves traversing the lines in each region and subtracting a line in the first data structure from its corresponding line in the second data structure.

The above rules will be further explained by means of an example in which region 808 illustrated in FIG. 10B, and represented by data structure 810, will be subtracted from region 802 in FIG. 10A. Application of rules (1)-(5), for the given regions, results in the following:

(Step 1) Top Row:
[1,2] − [1,2] = 0 Rule (2)
[7,7] − [1,2] = [7,7], [7,7] − [6,11] = 0 Rules (1), (2)
[11,11] − [1,2] = [11,11], [11,11] − [6,11] = 0 Rules (1), (2)
(Step 2) Second Row:
[1,3] − [2,3] = [1,1], [1,1] − [7,7] = [1,1], [1,1] − Rules (3), (1), (1)
[11,11] = [1,1]
[7,11] − [2,3] = [7,11], [7,11] − [7,7] = [7,11], [7,11] − Rules (1), (1), (3)
[11,11] = [7,10]
(Step 3) Third Row:
[1,11] − [1,11] = 0 Rule (2)
(Step 4) Lower Row:
[1,10] − [4,9] = [1,3] and [10,10] Rule (5)

In performing the subtraction, each segment 806d and 806e in row 1 of data structure 810 is subtracted from each segment 806a, 806b, and 806c in row 1 of data structure 804. Thus, as can be seen for the top row under Step 1 above, segment 806d is subtracted from segment 806a using Rule (2). The application of Rule (2) results in a run-length segment that contains no pixels, i.e., a range of 0. Intuitively, it can be seen that segment 806d is the same as segment 806a and that subtraction of the two should result in 0, as it does under Rule (2). Next, segment 806d is subtracted from segment 806b, using Rule (1). Intuitively, because the pixel range described by segment 806d does not overlap the range described by segment 806b, subtracting 806d from 806b should have no effect. Indeed, application of rule (1) has no effect on segment 806b.

Now, however, segment 806e must be subtracted from segment 806b. As can be seen, segment 806e overlaps segment 806b entirely. Therefore, application of rule (2), which is the appropriate rule for these two segments, results in 0. In other words, if region 802 is a target mass, and region 808 defines an expected thermal dose, then the dose represented by segment 806e will completely ablate the portion of the target mass represented by segment 806b. The same result occurs for the subtraction of segments 806e and 806d from segment 806c. The subtraction then continues for each row as illustrated by steps 2, 3, and 4 above. The resulting region is illustrated in FIG. 10C, which actually consists of four separate regions 812, 814, 816, and 818. These regions 812, 814, 816, and 818 are represented by data structure 820 and associated linked lists of run-length segments 806. It is these untreated regions 812, 814, 816, and 818 that will require the treatment plan to be updated by returning to the planning stage in step 720.

An alternative method for updating the treatment plan involves eliminating steps 710 and 712 in FIG. 9. Instead, the system accepts a target mass 914 to be treated and follows the steps illustrated in FIG. 11. First, in step 902, it is determined if there is an untreated region 914. If there is, then treatment site 916 is selected in step 904, and thermal dose properties are estimated so as to deliver the appropriate thermal dose the treatment site 916. Then, in step 906, the thermal dose is applied to treatment site 916 resulting in a treated region 918. In step 908, the size of treated region is calculated and stored as a linked-list so that in step 910 the treated region can be subtracted from the untreated region 920 in order to determine the remaining untreated region. The process then reverts to step 902, and a new treatment site is selected. Once the entire target mass 914 is treated, there will not be any untreated regions and the process will exit.

Referring back to FIG. 9, after the treatment is complete, it is determined in step 726 whether to restart a treatment or to exit. Additionally, if there is insufficient information or a fatal error occurs in any of steps 704-716, the process will automatically go to step 726, where it can be decide to proceed with a new treatment plan or to exit altogether.

Thus, on a most detailed and narrow aspect, the invention provides methods for constructing a three-dimensional thermal dose treatment plan, including:

Although many aspects and features of the present invention have been described and illustrated in the above description and drawings of the preferred embodiments, it is understood that numerous changes and modifications can be made by those skilled in the art without departing from the invention concepts disclosed herein.

The invention, therefore, is not to be restricted, except by the following claims and their equivalents.

Freundlich, David, Vitek, Shuki, Vortman, Jacob, Yagel, Roni, Brenner, Naama

Patent Priority Assignee Title
10092367, Mar 18 2014 MONTERIS MEDICAL CORPORATION Image-guided therapy of a tissue
10188462, Jun 27 2012 MONTERIS MEDICAL CORPORATION Image-guided therapy of a tissue
10327830, Apr 01 2015 MONTERIS MEDICAL CORPORATION Cryotherapy, thermal therapy, temperature modulation therapy, and probe apparatus therefor
10342632, Mar 18 2014 MONTERIS MEDICAL CORPORATION Image-guided therapy of a tissue
10548678, Jun 27 2012 MONTERIS MEDICAL CORPORATION Method and device for effecting thermal therapy of a tissue
10610317, Jun 27 2012 MONTERIS MEDICAL CORPORATION Image-guided therapy of a tissue
10675113, Mar 18 2014 MONTERIS MEDICAL CORPORATION Automated therapy of a three-dimensional tissue region
10835215, Sep 12 2012 CONVERGENT LIFE SCIENCES, INC Method and apparatus for laser ablation under ultrasound guidance
11672583, Apr 01 2015 MONTERIS MEDICAL CORPORATION Cryotherapy, thermal therapy, temperature modulation therapy, and probe apparatus therefor
8867811, Jun 02 2009 PROFOUND MEDICAL INC MR imaging guided therapy
8979871, Jun 27 2012 MONTERIS MEDICAL US, INC ; MONTERIS MEDICAL CORPORATION Image-guided therapy of a tissue
9211157, Jun 27 2012 MONTERIS MEDICAL CORPORATION Probe driver
9271794, Jun 27 2012 MONTERIS MEDICAL CORPORATION Monitoring and noise masking of thermal therapy
9333038, Jun 15 2000 MONTERIS MEDICAL CORPORATION Hyperthermia treatment and probe therefore
9387042, Jun 15 2000 MONTERIS MEDICAL CORPORATION Hyperthermia treatment and probe therefor
9433383, Mar 18 2014 MONTERIS MEDICAL CORPORATION Image-guided therapy of a tissue
9486170, Mar 18 2014 MONTERIS MEDICAL CORPORATION Image-guided therapy of a tissue
9492121, Mar 18 2014 MONTERIS MEDICAL CORPORATION Image-guided therapy of a tissue
9504484, Mar 18 2014 MONTERIS MEDICAL CORPORATION Image-guided therapy of a tissue
9510909, Jun 27 2012 MONTERIS MEDICAL CORPORATION Image-guide therapy of a tissue
9687681, Jan 14 2008 PROFOUND MEDICAL INC Therapy system with temperature control
9700342, Mar 18 2014 MONTERIS MEDICAL CORPORATION Image-guided therapy of a tissue
9981148, Oct 22 2010 INSIGHTEC, LTD Adaptive active cooling during focused ultrasound treatment
Patent Priority Assignee Title
2795709,
3142035,
3942150, Aug 12 1974 The United States of America as represented by the Secretary of the Navy Correction of spatial non-uniformities in sonar, radar, and holographic acoustic imaging systems
3974475, Oct 07 1971 KONTRON INCORPORATED Method of and apparatus for focusing ultrasonic waves in a focal line
3992693, Dec 04 1972 The Bendix Corporation Underwater transducer and projector therefor
4000493, Apr 12 1971 Eastman Kodak Company Acoustooptic scanner apparatus and method
4074564, Apr 25 1974 DIASONICS DELAWARE, INC , A CORP OF DE Reconstruction system and method for ultrasonic imaging
4206653, Oct 02 1975 Thorn EMI Patents Limited Ultrasonic apparatus
4339952, Apr 26 1979 ONTARIO CANCER INSTITUTE, Cylindrical transducer ultrasonic scanner
4441486, Oct 27 1981 BOARD OF TRUSTEES OF LELAND STANFORD JR UNIVERSITY STANFORD UNIVERSITY Hyperthermia system
4454597, May 03 1982 The United States of America as represented by the Secretary of the Navy Conformal array compensating beamformer
4478083, Jun 30 1982 Siemens Aktiengesellschaft Plane reconstruction ultrasound tomography device
4505156, Jun 21 1983 Sound Products Company L.P. Method and apparatus for switching multi-element transducer arrays
4526168, May 14 1981 Siemens Aktiengesellschaft Apparatus for destroying calculi in body cavities
4537074, Sep 12 1983 Technicare Corporation Annular array ultrasonic transducers
4549533, Jan 30 1984 University of Illinois Apparatus and method for generating and directing ultrasound
4554925, Jul 07 1982 PICKER INTERNATIONAL LIMITED, A BRITISH COMPANY Nuclear magnetic resonance imaging method
4586512, Jun 26 1981 Thomson-CSF Device for localized heating of biological tissues
4636964, May 04 1982 Krautkramer-Branson, Inc. Method and system for generating and adjusting a predetermined quantity of mutually independent direct current voltages
4662222, Dec 21 1984 Techniscan, Inc Apparatus and method for acoustic imaging using inverse scattering techniques
4858597, Jun 01 1983 Richard Wolf GmbH Piezoelectric transducer for the destruction of concretions within an animal body
4865042, Aug 16 1985 Hitachi, Ltd. Ultrasonic irradiation system
4888746, Sep 24 1987 Richard Wolf GmbH Focussing ultrasound transducer
4889122, Nov 29 1985 Aberdeen University Divergent ultrasound arrays
4893284, May 27 1988 General Electric Company Calibration of phased array ultrasound probe
4893624, Jun 21 1988 MASSACHUSETTS INSTITUTE OF TECHNOLOGY, 77 MASSACHUSETTS AVENUE, CAMBRIDGE, MASSACHUSETTS A CORP OF MA Diffuse focus ultrasound hyperthermia system
4937767, Dec 24 1986 HEWLETT-PACKARD COMPANY, A CORP OF CA Method and apparatus for adjusting the intensity profile of an ultrasound beam
5209221, Mar 01 1988 RIEDLINGER, RAINER E Ultrasonic treatment of pathological tissue
5211160, Dec 17 1990 EBI, LLC Ultrasonic orthopedic treatment head and body-mounting means therefor
5247935, Mar 19 1992 Insightec Ltd Magnetic resonance guided focussed ultrasound surgery
5271400, Apr 01 1992 General Electric Company Tracking system to monitor the position and orientation of a device using magnetic resonance detection of a sample contained within the device
5275165, Nov 06 1992 Insightec Ltd Magnetic resonance guided ultrasound therapy system with inclined track to move transducers in a small vertical space
5291890, Aug 29 1991 Insightec Ltd Magnetic resonance surgery using heat waves produced with focussed ultrasound
5307812, Mar 26 1993 Insightec Ltd Heat surgery system monitored by real-time magnetic resonance profiling
5307816, Aug 21 1991 Kabushiki Kaisha Toshiba Thrombus resolving treatment apparatus
5318025, Apr 01 1992 General Electric Company Tracking system to monitor the position and orientation of a device using multiplexed magnetic resonance detection
5323779, Mar 26 1993 Insightec Ltd Heat surgery system monitored by real-time magnetic resonance temperature profiling
5327884, Mar 26 1993 Insightec Ltd Heat surgery system monitored by real-time magnetic resonance temperature profiling
5329930, Oct 12 1993 General Electric Company Phased array sector scanner with multiplexed acoustic transducer elements
5368031, Aug 29 1993 Insightec Ltd Magnetic resonance surgery using heat waves produced with a laser fiber
5368032, Nov 09 1993 TXSONICS, LTD Manually positioned focussed energy system guided by medical imaging
5379642, Jul 19 1993 DIASONICS, INC Method and apparatus for performing imaging
5391140, Jan 29 1993 Siemens Aktiengesellschaft Therapy apparatus for locating and treating a zone in the body of a life form with acoustic waves
5413550, Jul 21 1993 ACCELERATED CARE PLUS CORP Ultrasound therapy system with automatic dose control
5435304, Apr 24 1992 Siemens Aktiengesellschaft Method and apparatus for therapeutic treatment with focussed acoustic waves switchable between a locating mode and a therapy mode
5435312, May 31 1991 THERMOTREX CORP Acoustic imaging device
5443068, Sep 26 1994 Insightec Ltd Mechanical positioner for magnetic resonance guided ultrasound therapy
5474071, Mar 05 1991 Technomed Medical Systems Therapeutic endo-rectal probe and apparatus constituting an application thereof for destroying cancer tissue, in particular of the prostate, and preferably in combination with an imaging endo-cavitary-probe
5485839, Feb 28 1992 Kabushiki Kaisha Toshiba Method and apparatus for ultrasonic wave medical treatment using computed tomography
5490840, Sep 26 1994 Insightec Ltd Targeted thermal release of drug-polymer conjugates
5501655, Mar 31 1992 Massachusetts Institute of Technology Apparatus and method for acoustic heat generation and hyperthermia
5507790, Mar 21 1994 Method of non-invasive reduction of human site-specific subcutaneous fat tissue deposits by accelerated lipolysis metabolism
5520188, Nov 02 1994 THS INTERNATIONAL, INC Annular array transducer
5526814, Nov 09 1993 Insightec Ltd Automatically positioned focussed energy system guided by medical imaging
5526815, Jan 29 1993 SIEMENS AKTIENGESELLSCHAT Therapy apparatus for locating and treating a zone located in the body of a life form with acoustic waves
5549638, May 17 1994 Ultrasound device for use in a thermotherapy apparatus
5553618, Mar 12 1993 Kabushiki Kaisha Toshiba Method and apparatus for ultrasound medical treatment
5573497, Nov 30 1994 Technomed Medical Systems; INSTITUT NATIONAL High-intensity ultrasound therapy method and apparatus with controlled cavitation effect and reduced side lobes
5582578, Aug 01 1995 Duke University Method for the comminution of concretions
5590653, Mar 10 1993 Kabushiki Kaisha Toshiba Ultrasonic wave medical treatment apparatus suitable for use under guidance of magnetic resonance imaging
5590657, Nov 06 1995 MICHIGAN, UNIVERSITY OF, THE REGENTS Phased array ultrasound system and method for cardiac ablation
5601526, Dec 20 1991 Technomed Medical Systems Ultrasound therapy apparatus delivering ultrasound waves having thermal and cavitation effects
5605154, Jun 06 1995 Duke University Two-dimensional phase correction using a deformable ultrasonic transducer array
5617371, Feb 08 1995 DIAGNOSTIC RETRIEVAL SYSTEMS, INC , A CORP OF DE Method and apparatus for accurately determing the location of signal transducers in a passive sonar or other transducer array system
5617857, Jun 06 1995 IMAGE GUIDED TECHNOLOGIES, INC Imaging system having interactive medical instruments and methods
5643179, Dec 28 1993 Kabushiki Kaisha Toshiba Method and apparatus for ultrasonic medical treatment with optimum ultrasonic irradiation control
5662170, Nov 22 1994 Baker Hughes Incorporated Method of drilling and completing wells
5665054, Jan 27 1994 TECHNOMED MEDICAL SYSTEMS, S A Control method for hyperthermia treatment apparatus using ultrasound
5666954, Mar 05 1991 Technomed Medical Systems Therapeutic endo-rectal probe, and apparatus constituting an application thereof for destroying cancer tissue, in particular of the prostate, and preferably in combination with an imaging endo-cavitary-probe
5676673, Sep 13 1995 GE Medical Systems Global Technology Company, LLC Position tracking and imaging system with error detection for use in medical applications
5687729, Jun 22 1994 Siemens Aktiengesellschaft Source of therapeutic acoustic waves introducible into the body of a patient
5694936, Sep 17 1994 Kabushiki Kaisha Toshiba Ultrasonic apparatus for thermotherapy with variable frequency for suppressing cavitation
5711300, Aug 16 1995 Insightec Ltd Real time in vivo measurement of temperature changes with NMR imaging
5722411, Mar 12 1993 Kabushiki Kaisha Toshiba Ultrasound medical treatment apparatus with reduction of noise due to treatment ultrasound irradiation at ultrasound imaging device
5739625, May 09 1994 ATLAS ELEKTRONIK UK LIMITED Segmented ring transducers
5743863, Jan 22 1993 Technomed Medical Systems and Institut National High-intensity ultrasound therapy method and apparatus with controlled cavitation effect and reduced side lobes
5752515, Aug 21 1996 BRIGHAM & WOMEN S HOSPITAL Methods and apparatus for image-guided ultrasound delivery of compounds through the blood-brain barrier
5759162, Mar 10 1992 Siemens Aktiengesellschaft Method and apparatus for ultrasound tissue therapy
5762616, Mar 15 1996 Exogen, Inc. Apparatus for ultrasonic treatment of sites corresponding to the torso
5769790, Oct 25 1996 Insightec Ltd Focused ultrasound surgery system guided by ultrasound imaging
5810008, Dec 03 1996 Brainlab AG Apparatus and method for visualizing ultrasonic images
5817036, Feb 20 1997 Insightec Ltd System and method for treatment of a prostate with a phase fresnel probe
5823962, Sep 02 1996 Siemens Aktiengesellschaft Ultrasound transducer for diagnostic and therapeutic use
5873845, Mar 17 1997 Insightec Ltd Ultrasound transducer with focused ultrasound refraction plate
5897495, Mar 10 1993 Kabushiki Kaisha Toshiba Ultrasonic wave medical treatment apparatus suitable for use under guidance of magnetic resonance imaging
5938600, Dec 14 1995 U S PHILIPS CORPORATION Method and device for heating by means of ultrasound
5938608, Mar 03 1995 Siemens Aktiengesellschaft Therapy apparatus for carrying out treatment with focused ultrasound
5947900, Apr 13 1998 General Electric Company Dynamic scan plane tracking using MR position monitoring
5984881, Mar 31 1995 Kabushiki Kaisha Toshiba Ultrasound therapeutic apparatus using a therapeutic ultrasonic wave source and an ultrasonic probe
6004269, Jul 01 1993 Boston Scientific Scimed, Inc Catheters for imaging, sensing electrical potentials, and ablating tissue
6023636, Jun 25 1997 AMRIS PATENTE VERWALTUNGS GMBH & CO KG Magnetic resonance apparatus and method for determining the location of a positionable object in a subject
6042556, Sep 04 1998 University of Washington Method for determining phase advancement of transducer elements in high intensity focused ultrasound
6071239, Oct 27 1997 Method and apparatus for lipolytic therapy using ultrasound energy
6113558, Sep 29 1997 Angiosonics Inc. Pulsed mode lysis method
6113559, Dec 29 1997 DERMAFOCUS LLC Method and apparatus for therapeutic treatment of skin with ultrasound
6128522, May 23 1997 Koninklijke Philips Electronics N V MRI-guided therapeutic unit and methods
6128958, Sep 11 1997 The Regents of the University of Michigan Phased array system architecture
6193659, Jul 15 1997 Siemens Medical Solutions USA, Inc Medical ultrasonic diagnostic imaging method and apparatus
6242915, Aug 27 1999 General Electric Company Field-frequency lock system for magnetic resonance system
6246896, Nov 24 1998 General Electric Company MRI guided ablation system
6263230, May 08 1997 BARD ACCESS SYSTEMS, INC System and method to determine the location and orientation of an indwelling medical device
6267734, Mar 31 1995 Kabushiki Kaisha Toshiba Ultrasound therapeutic apparatus
6289233, Nov 25 1998 General Electric Company High speed tracking of interventional devices using an MRI system
6309355, Dec 22 1998 The Regents of the University of Michigan Method and assembly for performing ultrasound surgery using cavitation
6317619, Jul 29 1999 Koninklijke Philips Electronics N V Apparatus, methods, and devices for magnetic resonance imaging controlled by the position of a moveable RF coil
6322527, Apr 18 1997 Exogen, Inc Apparatus for ultrasonic bone treatment
6334846, Mar 31 1995 Kabushiki Kaisha Toshiba Ultrasound therapeutic apparatus
6374132, May 23 1997 Koninklijke Philips Electronics N V MRI-guided therapeutic unit and methods
6392330, Jun 05 2000 Pegasus Technologies Ltd. Cylindrical ultrasound receivers and transceivers formed from piezoelectric film
6397094, Jan 09 1998 Koninklijke Philips Electronics N V MR method utilizing microcoils situated in the examination zone
6413216, Dec 22 1998 REGENTS OF THE UNIVERSITY OF MICHIGAN, THE Method and assembly for performing ultrasound surgery using cavitation
6419648, Apr 21 2000 Insightec Ltd Systems and methods for reducing secondary hot spots in a phased array focused ultrasound system
6424597, Nov 27 1998 Commissariat a l'Energie Atomique Multielements ultrasonic contact transducer
6425867, Sep 18 1998 MIRABILIS MEDICA, INC Noise-free real time ultrasonic imaging of a treatment site undergoing high intensity focused ultrasound therapy
6428532, Dec 30 1998 GENERAL HOSPITAL CORPORATION, THE, D B A MASSACHUSETTS GENERAL HOSPITAL Selective tissue targeting by difference frequency of two wavelengths
6461314, Feb 02 1999 MISONIX, INC Intrabody hifu applicator
6475150, Dec 01 2000 The Regents of the University of California System and method for ultrasonic tomography
6478739, May 11 2001 The Procter & Gamble Company Ultrasonic breast examination system
6506154, Nov 28 2000 Insightec Ltd Systems and methods for controlling a phased array focused ultrasound system
6506171, Jul 27 2000 Insightec Ltd System and methods for controlling distribution of acoustic energy around a focal point using a focused ultrasound system
6511428, Oct 26 1998 Hitachi Medical Corporation Ultrasonic medical treating device
6522142, Dec 14 2001 Insightec Ltd MRI-guided temperature mapping of tissue undergoing thermal treatment
6543272, Apr 21 2000 Insightec Ltd Systems and methods for testing and calibrating a focused ultrasound transducer array
6554826, Apr 21 2000 Insightec Ltd Electro-dynamic phased array lens for controlling acoustic wave propagation
6559644, May 30 2001 Insightec Ltd MRI-based temperature mapping with error compensation
6566878, Sep 09 1999 Hitachi Medical Corporation Magnetic resonance imaging device and method therefor
6582381, Jul 31 2000 Insightec Ltd Mechanical positioner for MRI guided ultrasound therapy system
6599256, Sep 11 2000 OTSUKA MEDICAL DEVICES CO , LTD Occlusion of tubular anatomical structures by energy application
6612988, Aug 29 2000 Insightec Ltd Ultrasound therapy
6613004, Apr 21 2000 Insightec Ltd Systems and methods for creating longer necrosed volumes using a phased array focused ultrasound system
6613005, Nov 28 2000 Insightec Ltd Systems and methods for steering a focused ultrasound array
6618608, Nov 30 1999 Insightec Ltd Thermal imaging of fat and muscle using a simultaneous phase and magnitude double echo sequence
6618620, Nov 28 2000 INSIGHTEC, LTD Apparatus for controlling thermal dosing in an thermal treatment system
6626854, Dec 27 2000 Insightec Ltd Systems and methods for ultrasound assisted lipolysis
6626855, Nov 26 1999 OTSUKA MEDICAL DEVICES CO , LTD Controlled high efficiency lesion formation using high intensity ultrasound
6629929, Nov 08 2002 Koninklijke Philips Electronics N.V. Method and apparatus for automatically setting the transmit aperture and apodization of an ultrasound transducer array
6645162, Dec 27 2000 Insightec Ltd Systems and methods for ultrasound assisted lipolysis
6652461, Apr 15 1999 F.R.A.Y Project Ltd. Ultrasound device for three-dimensional imaging of internal structure of a body part
6666833, Nov 28 2000 Insightec Ltd Systems and methods for focussing an acoustic energy beam transmitted through non-uniform tissue medium
6676601, May 26 1999 Technomed Medical Systems, S.A.; Institut National de la Sante et de la Recherche Medicale (INSERM) Apparatus and method for location and treatment using ultrasound
6679855, Nov 07 2000 Method and apparatus for the correction of presbyopia using high intensity focused ultrasound
6705994, Jul 08 2002 Insightec Ltd Tissue inhomogeneity correction in ultrasound imaging
6719694, Dec 23 1999 OTSUKA MEDICAL DEVICES CO , LTD Ultrasound transducers for imaging and therapy
6733450, Jul 27 2000 Texas Systems, Board of Regents Therapeutic methods and apparatus for use of sonication to enhance perfusion of tissue
6735461, Jun 19 2001 Insightec Ltd Focused ultrasound system with MRI synchronization
6761691, Jul 21 2000 FUJIFILM Corporation Image forming method used in ultrasonic diagnosis, ultrasonic diagnostic apparatus, signal processing apparatus, and recording medium for recording signal processing program
6770031, Dec 15 2000 BRIGHAM AND WOMEN S HOSPITAL, INC Ultrasound therapy
6770039, Nov 09 2001 Duke University Method to reduce tissue injury in shock wave lithotripsy
6788619, Sep 04 2002 SHELL USA, INC Concentrating seismic energy in a selected target point in an underground formation
6790180, Dec 03 2001 Insightec Ltd Apparatus, systems, and methods for measuring power output of an ultrasound transducer
6824516, Mar 11 2002 MEDSCI TECHNOLOGIES, INC System for examining, mapping, diagnosing, and treating diseases of the prostate
6951540, May 10 2002 Regents of the University of Minnesota Ultrasound imaging system and method using non-linear post-beamforming filter
6961606, Oct 19 2001 Koninklijke Philips Electronics N V Multimodality medical imaging system and method with separable detector devices
7001379, Jun 25 1999 Boston Scientific Scimed, Inc Method and system for heating solid tissue
7077820, Oct 21 2002 JOHNSON & JOHNSON SURGICAL VISION, INC Enhanced microburst ultrasonic power delivery system and method
7094205, Apr 06 2001 ALFRED E. MANN INSTITUTE FOR BIOMEDICAL ENGINEERING AT THE UNIVERSITY OF SOUTHERN CALIFORNIA; ALFRED E MANN INSTITUTE FOR BIOMEDICAL ENGINEERING AT THE UNIVERSITY OF SOUTHERN CALIFORNIA High-resolution 3D ultrasonic transmission imaging
7128711, Mar 25 2002 Insightec Ltd Positioning systems and methods for guided ultrasound therapy systems
7155271, Nov 04 1998 Johns Hopkins University School of Medicine System and method for magnetic-resonance-guided electrophysiologic and ablation procedures
7175596, Oct 29 2001 Insightec Ltd System and method for sensing and locating disturbances in an energy path of a focused ultrasound system
7175599, Apr 17 2003 Brigham and Women's Hospital, Inc. Shear mode diagnostic ultrasound
7264592, Jun 28 2002 ALFRED E MANN INSTITUTE FOR BIOMEDICAL ENGINEERING AT THE UNIVERSITY OF SOUTHERN CALIFORNIA Scanning devices for three-dimensional ultrasound mammography
7264597, Oct 04 2001 INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Device and method for producing high-pressure ultrasonic pulses
7267650, Dec 16 2002 Cardiac Pacemakers, Inc Ultrasound directed guiding catheter system and method
7344509, Apr 17 2003 Shear mode therapeutic ultrasound
7377900, Jun 02 2003 Insightec Ltd Endo-cavity focused ultrasound transducer
7452357, Oct 22 2004 Cilag GmbH International System and method for planning treatment of tissue
7505805, Jul 11 2003 GE Medical Systems Global Technology Company, LLC Self-referencing/body motion tracking non-invasive internal temperature distribution measurement method and apparatus using magnetic resonance tomographic imaging technique
7505808, Apr 28 2004 SUNNYBROOK HEALTH SCIENCES CENTRE Catheter tracking with phase information
7510536, Sep 17 1999 University of Washington Ultrasound guided high intensity focused ultrasound treatment of nerves
7511501, May 11 2007 General Electric Company Systems and apparatus for monitoring internal temperature of a gradient coil
7535794, Aug 01 2006 INSIGHTEC, LTD.; Insightec Ltd Transducer surface mapping
7553284, Feb 02 2005 Focused ultrasound for pain reduction
7603162, Jan 28 2004 Siemens Healthcare GmbH Imaging tomography apparatus with fluid-containing chambers forming out-of-balance compensating weights for a rotating part
7611462, May 22 2003 Insightec Ltd Acoustic beam forming in phased arrays including large numbers of transducer elements
7652410, Aug 01 2006 Insightec Ltd Ultrasound transducer with non-uniform elements
7699780, Aug 11 2004 Insightec Ltd Focused ultrasound system with adaptive anatomical aperture shaping
20010031922,
20020035779,
20020082589,
20020188229,
20030004439,
20030060820,
20030187371,
20040030251,
20040068186,
20040122323,
20040147919,
20040210134,
20040236253,
20040267126,
20050033201,
20050096542,
20050131301,
20050203444,
20050240126,
20050251046,
20060052661,
20060052701,
20060052706,
20060058678,
20060106300,
20060173385,
20060184069,
20060206105,
20060229594,
20070016039,
20070055140,
20070066897,
20070073135,
20070098232,
20070167781,
20070197918,
20070219470,
20080027342,
20080031090,
20080033278,
20080082026,
20080108900,
20080183077,
20080228081,
20080312562,
20090088623,
20090096450,
20100056962,
CN1257414,
DE10102317,
DE4345308,
EP31614,
EP558029,
EP875203,
EP1132054,
EP1582886,
EP1591073,
EP1774920,
EP1790384,
FR2806611,
JP11313833,
JP2002505596,
JP5300910,
WO31614,
WO166189,
WO180709,
WO2058791,
WO3013654,
WO3070105,
WO3097162,
WO3098232,
WO2001058337,
WO200143640,
WO2004093686,
WO200558029,
WO2006018837,
WO2006025001,
WO2006087649,
WO2006119572,
WO2007073551,
WO2007093998,
WO2008039449,
WO2008050278,
WO2008119054,
WO200875203,
WO2009055587,
WO2009094554,
WO9100059,
WO9852465,
/
Executed onAssignorAssigneeConveyanceFrameReelDoc
Sep 08 2005InSightec Ltd.(assignment on the face of the patent)
Date Maintenance Fee Events
Nov 19 2012ASPN: Payor Number Assigned.
Dec 03 2014STOL: Pat Hldr no Longer Claims Small Ent Stat
Mar 05 2015M1553: Payment of Maintenance Fee, 12th Year, Large Entity.


Date Maintenance Schedule
Jan 01 20164 years fee payment window open
Jul 01 20166 months grace period start (w surcharge)
Jan 01 2017patent expiry (for year 4)
Jan 01 20192 years to revive unintentionally abandoned end. (for year 4)
Jan 01 20208 years fee payment window open
Jul 01 20206 months grace period start (w surcharge)
Jan 01 2021patent expiry (for year 8)
Jan 01 20232 years to revive unintentionally abandoned end. (for year 8)
Jan 01 202412 years fee payment window open
Jul 01 20246 months grace period start (w surcharge)
Jan 01 2025patent expiry (for year 12)
Jan 01 20272 years to revive unintentionally abandoned end. (for year 12)